RVMD · XBRL financial data

Revolution Medicines financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (RVMD's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	43	29	35	12	0	0
Research and development	132	187	253	423	592	987
General and administrative	21	30	41	76	97	195
Total operating expenses	154	217	294	499	690	1,182
Operating income (loss)	(111)	(188)	(258)	(487)	(690)	(1,182)
Interest income	2	1	9	47	87	91
Interest expense	0	0	0	0	0	24
Income tax expense (benefit)	(0)	0	(0)	(4)	(1)	0
Net income (loss)	(108)	(187)	(249)	(436)	(600)	(1,131)
Earnings per share, basic USD per share	(2.01)	(2.57)	(3.08)	(3.86)	(3.58)	(5.95)
Earnings per share, diluted USD per share	(2.01)	(2.57)	(3.08)	(3.86)	(3.58)	(5.95)
Weighted average shares, basic millions of shares	55	73	81	113	168	190
Weighted average shares, diluted millions of shares	55	73	81	113	168	190

Fiscal years (RVMD's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	104	108	161	696	543	384
Marketable securities	336	469	484	1,157	1,746	1,642
Prepaid and other current assets	7	7	11	25	38	49
Total current assets	454	590	660	1,879	2,328	2,075
Property and equipment, net	9	12	19	23	24	33
Right-of-use asset	27	60	55	77	118	132
Goodwill	15	15	15	15	15	15
Total assets	567	738	812	2,062	2,558	2,355
Accounts payable	13	14	21	62	54	65
Accrued liabilities	—	—	—	—	—	5
Total current liabilities	47	60	62	144	164	290
Lease liability, non-current	29	60	57	81	123	142
Total liabilities	93	135	127	236	293	723
Accumulated deficit	(266)	(453)	(701)	(1,138)	(1,738)	(2,869)
Total stockholders' equity	475	603	685	1,826	2,265	1,631
Total liabilities and equity	567	738	812	2,062	2,558	2,355
Common shares outstanding (cover page) millions of shares	73	74	90	165	186	198

Fiscal years (RVMD's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(108)	(187)	(249)	(436)	(600)	(1,131)
Stock-based compensation	9	21	31	62	79	118
Depreciation and amortization	3	3	4	—	—	—
Net cash from operating activities	(100)	(147)	(224)	(351)	(557)	(898)
Purchases of property and equipment	3	7	11	8	10	16
Net cash from investing activities	(234)	(142)	(24)	(343)	(554)	118
Proceeds from issuing common stock	420	281	248	324	728	0
Dividends paid	0	—	—	—	—	—
Net cash from financing activities	423	294	301	1,229	959	622
Net change in cash	88	5	53	536	(152)	(158)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Revolution Medicines	815	not reported	(387)*	214.3M	10.2 quarters	Q2 FY26 10-QJun 30, 2026
Biomarin Pharmaceutical	736	1,025	188*	193.7M	—	Q3 FY26 10-QSep 30, 2026
Jazz Pharmaceuticals	2,036	1,243	506*	64.2M	—	Q3 FY26 10-QSep 30, 2026
Corcept Therapeutics	99	340	143*	109.4M	—	Q3 FY26 10-QSep 30, 2026
Repligen	727	209	43*	63.9M	—	Q3 FY26 10-QSep 30, 2026
Madrigal Pharmaceuticals	515	431	121*	23.2M	—	Q3 FY26 10-QSep 30, 2026
Ionis Pharmaceuticals	350	268	566*	166.2M	—	Q2 FY26 10-QJun 30, 2026
BIO-TECHNE	265	321*	95*	156.8M	—	Q4 FY26 10-KJun 30, 2026
Exelixis	305	659	280*	244.0M	—	Q3 FY26 10-QOct 2, 2026

Not investment advice. Not affiliated with the U.S. SEC.